(PRA-027)-药物靶点：PR_专利_临床

概要

基本信息

药物类型

小分子化药

别名

WAY-257027、PRA 027

靶点

PR(孕激素受体)

作用机制

PR调节剂(孕激素受体调节剂)

治疗领域

肿瘤

在研适应症-

非在研适应症

平滑肌瘤

原研机构

Pfizer Inc.

在研机构-

非在研机构

Pfizer Inc.Wyeth AB

最高研发状态(全球)无进展临床1期

首次获批日期(全球)-

最高研发状态(中国)-

特殊审评-

结构

分子式C15H13N3O2S

InChIKeyOLHKCEIOFAUDPT-UHFFFAOYSA-N

CAS号1007581-62-5

关联

3

项与 PRA-027 相关的临床试验

NCT00543790 / Completed临床1期

A Randomized, Placebo-Controlled, Double-Blind, Sponsor-Unblinded, Multiple-Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PRA-027 Administered Orally To Cycling Or Postmenopausal Women

This is the first multiple-dose study in humans with PRA-027. This study will provide an assessment of the safety, tolerability, pharmacokinetics (how the drug is absorbed, metabolized and excreted by the body) and pharmacodynamics (a measure of whether the drug is active in the body) of PRA-027 after administration of 28 days of oral doses in women of childbearing potential (cycling) or postmenopausal women.

开始日期2007-11-01

申办/合作机构

Wyeth AB

NCT00444704 / Completed临床1期

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRA-027 Administered Orally to Healthy Japanese Females

The primary purpose of this study is to assess the safety and tolerability of ascending single oral doses of PRA-027 in healthy Japanese females. The secondary purpose is to provide the initial pharmacokinetic and pharmacodynamic profiles of PRA-027 in healthy Japanese female subjects.

开始日期2007-03-01

申办/合作机构

Wyeth AB

NCT00427544 / Completed临床1期

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRA-027 Administered Orally to Healthy Women of Nonchildbearing Potential

The primary purpose of this study is to asess the safety and tolerability of ascending single oral doses of PRA-027 in healthy women of nonchildbearing potential. The secondary purpose is to provide the initial pharmacokinetic (PK) and pharmacodynamic (PD) profile of PRA-027 in healthy women of nonchildbearing potential, and to evaluate the effect of a high-fat meal on the PK and PD of PRA-027 administered to healthy women of nonchildbearing potential.

开始日期2007-02-01

申办/合作机构

Wyeth AB

100 项与 PRA-027 相关的专利（医药）

登录后查看更多信息